dengue_mosquito_web

Philippine FDA orders Sanofi to pull dengue vaccine ads

pharmafile | January 5, 2017 | News story | Medical Communications, Sales and Marketing Philippines, Sanofi, Vaccine, dengue, virus 

Sanofi has suffered a major blow to its dengue immunisation programme in the Philippines after it was requested the company and its vaccine arm Sanofi Pasteur pull all advertisements for its preventative treatment Dengvaxia in the country.

Under legislation active since 1989 on the authority of the Philippine Food and Drug Administration, it is illegal to advertise any ethical or prescription pharmaceuticals in the region.

The government issued the order on December 13; the administration also reached out to broadcasters in an effort to pull the advertisements. According to the FDA, Sanofi did not respond until at least December 15:

“Since Sanofi has not complied, we have issued summons directing them to cease and desist from airing the advertisements and show cause why they should not be penalised for violating the law,” stated Philippines FDA director Nela Charade G. Puno.

Sanofi has since said it has taken down the advertisements in question, noting in a statement that the FDA’s backpedalling came as a “complete surprise” to the company:

“This apparent reversal of the FDA’s previous approval of the material and content for this disease prevention awareness campaign comes as a complete surprise to the company which was in continuous contact with the FDA to ensure compliance of this campaign before its launch in the Philippines on November 4. According to the terms of the CDO (Cease and Desist Order) from the FDA on this matter, we filed our answer on December 27 and took action to stop all campaign-related activities as directed by the Agency. Sanofi has also requested a meeting with the FDA to review the legal basis for this apparent decision reversal by the Agency.”

The company first announced the programme, the first public immunisation effort in the country, in April 2015; the Philippine FDA approved Dengvaxia in December later that year, after 20 years and $1.5 billion of development on Sanofi’s part.

Sanofi noted that its immunisation programme is designed to target those areas hit hardest by the dengue virus; Asia currently accounts for 70% of all global cases.

Matt Fellows

Related Content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Sanofi to acquire Inhibrx for approximately $1.7bn

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …

Latest content